- Home
- BLRX vs KPRX Comparison
BLRX vs KPRX Comparison
Compare BLRX & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- KPRX
- Stock Information
- Founded
- BLRX 2003
- KPRX 1998
- Country
- BLRX Israel
- KPRX United States
- Employees
- BLRX N/A
- KPRX N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BLRX Health Care
- KPRX Health Care
- Exchange
- BLRX Nasdaq
- KPRX Nasdaq
- Market Cap
- BLRX 10.3M
- KPRX 8.3M
- IPO Year
- BLRX 2011
- KPRX N/A
- Fundamental
- Price
- BLRX $2.93
- KPRX $3.18
- Analyst Decision
- BLRX Buy
- KPRX Strong Buy
- Analyst Count
- BLRX 2
- KPRX 1
- Target Price
- BLRX $26.00
- KPRX $10.00
- AVG Volume (30 Days)
- BLRX 30.2K
- KPRX 10.5K
- Earning Date
- BLRX 05-27-2025
- KPRX 05-09-2025
- Dividend Yield
- BLRX N/A
- KPRX N/A
- EPS Growth
- BLRX N/A
- KPRX N/A
- EPS
- BLRX N/A
- KPRX 0.87
- Revenue
- BLRX $28,940,000.00
- KPRX $16,020,000.00
- Revenue This Year
- BLRX N/A
- KPRX N/A
- Revenue Next Year
- BLRX N/A
- KPRX N/A
- P/E Ratio
- BLRX N/A
- KPRX $3.56
- Revenue Growth
- BLRX 502.92
- KPRX N/A
- 52 Week Low
- BLRX $2.30
- KPRX $2.51
- 52 Week High
- BLRX $35.60
- KPRX $5.76
- Technical
- Relative Strength Index (RSI)
- BLRX 48.07
- KPRX 55.96
- Support Level
- BLRX $2.30
- KPRX $2.64
- Resistance Level
- BLRX $3.09
- KPRX $3.25
- Average True Range (ATR)
- BLRX 0.22
- KPRX 0.19
- MACD
- BLRX 0.06
- KPRX 0.06
- Stochastic Oscillator
- BLRX 79.33
- KPRX 74.32
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.